Factors Affecting the Price of Cyramza

Cyramza (ramucirumab)’s price is shaped by multiple factors. 

Factors Affecting the Price of Cyramza

High R&D costs for developing this VEGF receptor antagonist and conducting clinical trials for various cancers (e.g., gastric, lung) are a major driver. Patent exclusivity allows Eli Lilly to maintain market dominance, enabling premium pricing. 

Production complexities, such as biologic manufacturing and strict quality control, inflate costs. Market demand for anti-angiogenic therapies in advanced cancers and regional healthcare policies (e.g., insurance coverage) also influence patient out-of-pocket expenses.